Secondary progressive multiple sclerosis: Current knowledge and future challenges

Lancet Neurology

Volumn 5, Issue 4, 2006, Pages 343-354

  Rovaris, Marco ^a   Confavreux, Christian ^b   Furlan, Roberto ^a   Kappos, Ludwig ^c   Comi, Giancarlo ^a   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PLACEBO;

DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RECURRENT DISEASE; RELIABILITY; REVIEW; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; DIAGNOSTIC IMAGING; DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 33644974688     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70410-0     Document Type: Review

References (144)

1. GA Schumacher, G Beebe, RF Kibler Problems of experimental trials of therapy in MS: report by the panel on the evaluation of experimental trials of therapy in MS Ann N Y Acad Sci 122 1965 552 568
2. CM Poser, DW Paty, L Scheinberg New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 1983 227 231
3. C Confavreux, DAS Compston, OR Hommes EDMUS, a European Database for Multiple Sclerosis J Neurol Neurosurg Psychiatry 55 1992 671 676
4. AJ Thompson, CH Polman, DH Miller Primary progressive multiple sclerosis Brain 120 1997 1085 1096
5. WI McDonald, A Compston, G Edan Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis Ann Neurol 50 2001 121 127
6. FD Lublin, SC Reingold for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Defining the clinical course of multiple sclerosis: results of an international survey Neurology 46 1996 907 911
7. C Confavreux, DAS Compston The natural history of multiple sclerosis DAS Compston McAlpine's multiple sclerosis 4th edn. 2005 Churchill-Livingstone London
8. D McAlpine, ND Compston Some aspects of the natural history of disseminated sclerosis: incidence, course and prognosis, factors affecting onset and course Q J Med 21 1952 135 167
9. C Confavreux L'histoire naturelle de la sclérose en plaques: etude par informatique de 349 observations 1977 Thèse de Médecine, Université Claude Bernard-Lyon Lyon, France
10. C Confavreux, G Aimard, M Devic Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients Brain 103 1980 281 300
11. S Vukusic, C Confavreux Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis J Neurol Sci 206 2003 135 137
12. T Broman, O Andersen, L Bergmann Clinical studies on multiple sclerosis I: presentation of an incidence material from Gothenburg Acta Neurol Scand 63 1981 6 33
13. M Eriksson, O Andersen, B Runmarker Long-term tollow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis Mult Scler 9 2003 260 274
14. BG Weinshenker, B Bass, GP Rice The natural history of multiple sclerosis: a geographically based study I: clinical course and disability Brain 112 1989 133 146
15. MP Amato, G Ponziani A prospective study on the prognosis of multiple sclerosis Neurol Sci 21 suppl 2 2000 831 838
16. KM Myhr, T Riise, C Vedeler Disability an prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension Mult Scler 7 2001 59 65
17. R Müller Studies on disseminated sclerosis: with special reference to symptomatology, course and prognosis Acta Med Scand 133 suppl 222 1949 1 214
18. R Müller Course and prognosis of disseminated sclerosis in relation to age at onset Arch Neurol Psychiatry 66 1951 561 570
19. T Riise, M Gronning, O Fernandez Early prognostic factors for disability in multiple sclerosis, a European multicenter study Acta Neurol Scand 85 1992 212 218
20. B Runmarker, O Andersen Prognostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up Brain 116 1993 117 134
21. M Trojano, C Avolio, C Manzari Multivariate analysis of predictive factors of multiple sclerosis with a validated method to assess clinical events J Neurol Neurosurg Psychiatry 58 1995 300 306
22. C Confavreux, S Vukusic, P Adeleine Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 2003 770 782
23. JF Kurtzke Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
24. C Confavreux, S Vukusic, T Moreau, P Adeleine Relapses and progression of disability in multiple sclerosis N Eng J Med 343 2000 1430 1438
25. S Vukusic, C Confavreux Primary and secondary progressive multiple sclerosis J Neurol Sci 206 2003 153 155
26. JM Minderhoud, JH van der Hoeven, AJA Prange Course and prognosis of chronic progressive multiple sclerosis: results of an epidemiological study Acta Neurol Scand 78 1988 10 15
27. DA Cottrell, M Kremenchutzky, GPA Rice The natural history of multiple sclerosis: a geographically based study 5: the clinical features and natural history of primary progressive multiple sclerosis Brain 122 1999 625 639
28. M Kremenchutzky, D Cottrell, G Rice The natural history of multiple sclerosis - a geographically based study 7: progressive-relapsing and relapsing-progressive multiple sclerosis, a re-evaluation Brain 122 1999 1941 1949
29. T Revesz, D Kidd, AJ Thompson, RO Barnard, WI McDonald A comparison of the pathology of primary and secondary progressive multiple sclerosis Brain 117 1994 759 765
30. JW Prineas, EE Kwon, ES Cho Immunopathology of secondary-progressive multiple sclerosis Ann Neurol 50 2001 646 657
31. A Kutzelnigg, CF Lucchinetti, C Stadelmann Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain 128 2005 2705 2712
32. B Serafini, B Rosicarelli, R Magliozzi, E Stigliano, F Aloisi Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis Brain Pathol 14 2004 164 174
33. SS Soldan, AI Alvarez Retuerto, NL Sicotte, RR Voskuhl Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis J Neuroimmunol 146 2004 209 215
34. TL Sorensen, F Sellebjerg Distinct chemokine receptor and cytokine expression profile in secondary progressive MS Neurology 57 2001 1371 1376
35. C Trebst, TL Sorensen, P Kivisakk CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis Am J Pathol 159 2001 1701 1710
36. R Furlan, M Rovaris, M Khademi Immunological patterns identifying disease course and disease evolution in multiple sclerosis patients J Neuroimmunol 165 2005 192 200
37. MJ Eikelenboom, J Killestein, T Izeboud Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS J Neuroimmunol 158 2005 222 230
38. MJ Eikelenboom, J Killestein, BM Uitdehaag, CH Polman Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis Mult Scler 11 2005 520 523
39. AJ Thompson, AG Kermode, D Wicks Major differences in the dynamics of primary and secondary progressive multiple sclerosis Ann Neurol 29 1991 53 62
40. M Filippi, G Iannucci, C Tortorella Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI Neurology 52 1999 588 594
41. M Rovaris, M Bozzali, G Santuccio In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis Brain 124 2001 2540 2549
42. VL Stevenson, DH Miller, M Rovaris Primary and transitional progressive MS: a clinical and MRI cross-sectional study Neurology 52 1999 839 845
43. GJ Lycklama á Nijeholt, MAA van Walderveen, JA Castelijins Brain and spinal cord abnormalities in multiple sclerosis: correlation between MRI parameters, clinical subtypes, and symptoms Brain 121 1998 687 697
44. PD Molyneux, GJ Barker, F Barkhof Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS Neurology 57 2001 2191 2197
45. M Filippi, P Rossi, A Campi, B Colombo, C Pereira, G Comi Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability AJNR Am J Neuroradiol 18 1997 1549 1556
46. JA Koziol, S Wagner, HP Adams Assessing information in T2-weighted MRI scans from secondary progressive MS patients Neurology 51 1998 228 233
47. JS Wolinsky, PA Narayana, JH Noseworthy Linomide in relapsing and secondary progressive multiple sclerosis: MRI results Neurology 54 2000 1734 1741
48. N Tubridy, AJ Coles, P Molyneux Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features Brain 121 1998 225 231
49. PD Molyneux, M Filippi, F Barkhof Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis Ann Neurol 43 1998 332 339
50. L Kappos, D Moeri, EW Radue Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis Lancet 353 1999 964 969
51. ME Smith, LA Stone, PS Albert Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions Ann Neurol 33 1993 480 489
52. K Morgen, NO Jeffries, R Stone Ring-enhancement in multiple sclerosis: marker of disease severity Mult Scler 7 2001 167 171
53. L Truyen, JHTM van Waesberghe, MAA van Walderveen Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis Neurology 47 1997 1469 1476
54. C Tortorella, B Viti, M Bozzali A magnetization transfer histogram study of normal appearing brain tissue in multiple sclerosis Neurology 54 2000 186 193
55. MAA van Walderveen, GJ Lycklama à Nijeholt, HJ Ader Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis Arch Neurol 58 2001 76 81
56. A Minneboo, BMJ Uitdehaag, HJ Ader, F Barkhof, CH Polman, JA Casteljins Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients Neurology 65 2005 56 61
57. NA Losseff, L Wang, HM Lai Progressive cerebral atrophy in multiple sclerosis: a serial MRI study Brain 119 1996 2009 2019
58. Y Ge, RI Grossman, JK Udupa Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis Radiology 214 2000 665 670
59. NF Kalkers, E Bergers, JA Castelijns Optimizing the association between disability and biological markers in MS Neurology 57 2001 1253 1258
60. X Lin, LD Blumhardt Inflammation and atrophy in multiple sclerosis: MRI associations with disease course J Neurol Sci 189 2001 99 104
61. E Pagani, MA Rocca, A Gallo Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype Am J Neuroradiol 26 2005 341 346
62. M Filippi, A Campi, B Colombo A spinal cord MRI study of benign and secondary progressive multiple sclerosis J Neurol 243 1996 502 505
63. NA Losseff, SL Webb, JI O'Riordan Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression Brain 119 1996 701 708
64. X Lin, CR Tench, B Turner, LD Blumhardt, CS Constantinescu Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β-1a (Rebif) treatment trial J Neurol Neurosurg Psychiatry 74 2003 1090 1094
65. VL Stevenson, SM Leary, NA Losseff Spinal cord atrophy and disability in MS: a longitudinal study Neurology 51 1998 234 238
66. P Valsasina, MA Rocca, F Agosta Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients NeuroImage 26 2005 822 828
67. NF Kalkers, N Ameziane, JCJ Boost, A Minneboo, CH Polman, F Barkhof Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype Arch Neurol 59 2002 1572 1576
68. M Rovaris, F Agosta, MP Sormani Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study Brain 126 2003 2323 2332
69. M Rovaris, M Bozzali, G Iannucci Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis Arch Neurol 59 2002 1406 1412
70. M Rovaris, A Gallo, P Valsasina Short-term accrual of grey matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI NeuroImage 24 2005 1139 1146
71. MP Sormani, P Bruzzi, K Beckmann MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b Neurology 60 2003 1462 1466
72. DH Miller, PD Molyneux, GJ Barker Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial Ann Neurol 46 1999 850 859
73. GP Rice, M Filippi, G Comi Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial Neurology 54 2000 1145 1155
74. DKB Li, GJ Zhao, DW Paty Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results Neurology 56 2001 1505 1513
75. GL Mancardi, R Saccardi, M Filippi Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS Neurology 57 2001 62 68
76. PD Molyneux, L Kappos, C Polman The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis Brain 123 2000 2256 2263
77. F Barkhof, JH van Waesberghe, M Filippi T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment Brain 124 2001 1396 1402
78. M Filippi, M Rovaris, G Iannucci, S Mennea, MP Sormani, G Comi Whole brain volume changes in patients with progressive MS treated with cladribine Neurology 55 2000 1714 1718
79. M Filippi, M Rovaris, GPA Rice The effect of cladribine on T1 'black hole' changes in progressive MS J Neurol Sci 176 2000 42 44
80. M Inglese, GL Mancardi, E Pagani Brain tissue loss occurs after suppression of enhancement in MS patients treated with AHSCT J Neurol Neurosurg Psychiatry 75 2004 643 644
81. M Filippi, RI Grossman, G Comi Magnetization transfer in multiple sclerosis Neurology 53 suppl 3 1999 S40 S45
82. M Rovaris, A Gass, R Bammer Diffusion MRI in multiple sclerosis Neurology 65 2005 1526 1532
83. JC Bot, EL Blezer, W Kamphorst The spinal cord in multiple sclerosis: relationship of high spatial-resolution quantitative MR imaging findings to histopathologic results Radiology 233 2004 531 540
84. M Filippi, DL Arnold, G Comi Magnetic resonance spectroscopy in multiple sclerosis 2000 Springer-Verlag Milan, Italy
85. M Filippi, M Inglese, M Rovaris Magnetization transfer imaging to monitor the evolution of MS: a one-year follow up study Neurology 55 2000 940 946
86. NF Kalkers, RQ Hintzen, JH van Waesberghe Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy J Neurol Sci 184 2001 155 162
87. Y Ge, RI Grossman, JK Udupa, JS Babb, LJ Mannon, JC McGowan Magnetization transfer ratio histogram analysis of normal-appearing gray matter and normal-appearing white matter in multiple sclerosis J Comput Assist Tomogr 26 2002 62 68
88. JH van Waesberghe, W Kamphorst, CJ De Groot Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability Ann Neurol 46 1999 747 754
89. K Schmierer, F Scaravilli, DR Altmann, GJ Barker, DH Miller Magnetization transfer ratio and myelin in post mortem multiple sclerosis brain Ann Neurol 56 2004 407 415
90. MA Rocca, G Mastronardo, M Rodegher, G Comi, M Filippi Long term changes of MT-derived measures from patients with relapsing-remitting and secondary-progressive multiple sclerosis Am J Neuroradiol 20 1999 821 827
91. M Inglese, JHTM van Waesberghe, M Rovaris The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS Neurology 60 2003 853 860
92. M Filippi, M Bozzali, MA Horsfield A conventional and magnetization transfer MRI study of the cervical cord in patients with multiple sclerosis Neurology 54 2000 207 213
93. M Rovaris, M Bozzali, G Santuccio Relative contributions of brain and cervical cord pathology to MS disability: a study with MTR histogram analysis J Neurol Neurosurg Psychiatry 69 2000 723 727
94. AG Droogan, CA Clark, DJ Werring, GJ Barker, WI McDonald, DH Miller Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging Magn Reson Imaging 17 1999 653 661
95. AO Nusbaum, CY Tang, TC Wei, MS Buchsbaum, SW Atlas Whole-brain diffusion MR histograms differ between MS subtypes Neurology 54 2000 1421 1426
96. M Filippi, M Cercignani, M Inglese, MA Horsfield, G Comi Diffusion tensor magnetic resonance imaging in multiple sclerosis Neurology 56 2001 304 311
97. O Ciccarelli, DJ Werring, CA Wheeler-Kingshott Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations Neurology 56 2001 926 933
98. M Cercignani, M Inglese, E Pagani, G Comi, M Filippi Mean diffusivity and fractional anisotropy histograms in patients with multiple sclerosis Am J Neuroradiol 22 2001 952 958
99. M Cercignani, M Bozzali, G Iannucci, G Comi, M Filippi Intra-voxel and inter-voxel coherence in patients with multiple sclerosis assessed using diffusion tensor MRI J Neurol 249 2002 875 883
100. M Bozzali, M Cercignani, MP Sormani, G Comi, M Filippi Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging Am J Neuroradiol 23 2002 985 988
101. Vrenken H, Geurts JJG, Knol DL, et al. Whole-brain T1-mapping in multiple sclerosis: global changes of normal-appearing grey and white matter. Radiology (in press).
102. L Vaithianathar, CR Tench, PS Morgan, CS Constantinescu Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis: a quantitative T1 relaxation time mapping approach J Neurol 250 2003 307 315
103. MS Simmons, CG Frondosa, JT Coyle Immunocytochemical localization of N-acetyl aspartate with monoclonal antibodies Neuroscience 45 1991 37 45
104. L Fu, PM Matthews, N De Stefano Imaging axonal damage of normal-appearing white matter in multiple sclerosis Brain 121 1998 59 166
105. N De Stefano, PM Matthews, LQ Fu Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study Brain 121 1998 1469 1477
106. A Falini, G Calabrese, M Filippi Benign versus secondary progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability Am J Neuroradiol 19 1998 223 229
107. A Tourbah, JL Stievenart, O Gout Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis Neurology 53 1999 1091 1097
108. P Sarchielli, O Presciutti, GP Pelliccioli Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients Brain 122 1999 513 521
109. N De Stefano, S Narayanan, GS Francis Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability Arch Neurol 58 2001 65 70
110. E Adalsteinsson, A Langer-Gould, RJ Homer Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis Am J Neuroradiol 24 2003 1941 1945
111. H Vrenken, F Barkhof, BMJ Uitdehaag, JA Casteljins, CH Polman, PJW Pouwels MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter Magn Reson Med 53 2005 256 266
112. H Reddy, S Narayanan, R Arnoutelis Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis Brain 123 2000 2314 2320
113. P Pantano, GD Iannetti, F Caramia Cortical motor reorganization after a single attack of multiple sclerosis Brain 125 2002 1607 1615
114. MA Rocca, PM Matthews, D Caputo Evidence for widespread movement-associated functional MRI changes in patients with PPMS Neurology 58 2002 866 872
115. M Filippi, MA Rocca, A Falini Correlations between structural CNS damage and functional MRI changes in primary progressive MS NeuroImage 15 2002 537 546
116. MA Rocca, C Gavazzi, DM Mezzapesa A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis NeuroImage 19 2003 1770 1777
117. MA Rocca, B Colombo, A Falini Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes Lancet Neurol 4 2005 618 626
118. European Study Group on interferon β-1b in secondary progressive MS Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis Lancet 352 1998 1491 1497
119. L Kappos, C Polman, C Pozzilli, A Thompson, K Beckmann, F Dahlke Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS Neurology 57 2001 1969 1975
120. L Kappos, B Weinshenker, C Pozzilli Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials Neurology 63 2004 1779 1787
121. JA Freeman, AJ Thompson, R Fitzpatrick Interferon-β1b in the treatment of secondary progressive MS: impact on quality of life Neurology 57 2001 1870 1875
122. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results Neurology 56 2001 1496 1504
123. H Panitch, A Miller, D Paty Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study Neurology 63 2004 1788 1795
124. JA Cohen, GR Cutter, JS Fischer Benefit of interferon beta-1a on MSFC progression in secondary progressive MS Neurology 59 2002 679 687
125. X Wu, P Dastidar, H Kuusisto, M Ukkonen, H Huhtala, I Elovaara Increased disability and MRI lesions after discontinuation of IFN-β-1a in secondary progressive MS Acta Neurol Scand 112 2005 242 247
126. PS Sorensen, F Fazekas, M Lee Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis Eur J Neurol 9 2002 557 563
127. OR Hommes, PS Sorensen, F Fazekas Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial Lancet 364 2004 1149 1156
128. F Fazekas, PS Sorensen, M Filippi MRI results from the European study on intravenous immunoglobulin in secondary progressive multiple sclerosis (ESIMS) Mult Scler 11 2005 433 440
129. CH Polman, AJ Thompson, GJ Murray, WI McDonald Multiple sclerosis: the guide to treatment and management 5th edn. 2001 Demos Medical Publishing New York
130. DE Goodkin, RP Kinkel, B Weinstock-Guttman A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis Neurology 51 1998 239 245
131. A Lugaresi, C Caporale, D Farina Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis Neurol Sci 22 2001 209 210
132. L La Mantia, M Eoli, A Salmaggi, V Torri, C Milanese Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study Ital J Neurol Sci 19 1998 32 36
133. RD Currier, AF Haerer, EF Meydrech Low-dose methotrexate treatment of multiple sclerosis: a pilot study J Neurol Neurosurg Psychiatry 56 1993 1217 1218
134. DE Goodkin, RA Rudick, S Vanderburg-Medendorp Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis Ann Neurol 37 1995 30 40
135. DR Smith, HL Weiner Cyclophosophamide treatment of multiple sclerosis JA Cohen RA Rudick Multiple sclerosis therapeutics 2nd edn. 2003 Martin Dunitz London 483 500
136. The Canadian Cooperative Multiple Sclerosis Study Group The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis Lancet 337 1991 441 446
137. T Patti, E Reggio, F Palermo Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta J Neurol 251 2004 1502 1506
138. P Perini, P Gallo Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis J Neurol 250 2003 834 838
139. HP Hartung, R Gonsette, N Konig Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2002 2018 2025
140. H Krapf, SP Morrissey, O Zenker Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial Neurology 65 2005 690 695
141. AJ Coles, MG Wing, P Molyneux Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Ann Neurol 46 1999 296 304
142. A Paolillo, AJ Coles, P Molyneux Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H Neurology 53 1999 751 757
143. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (in press).
144. A Fassas, JR Passweg, A Anagnostopoulos Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study J Neurol 249 2002 1088 1097